Phase II study of combination therapy with 5-AZAcytidine, valproic acid, and all-trans retinoic acid [tretinoin] in patients with myelodysplastic syndromes and other myeloid malignancies who cannot receive intensive chemotherapy

Trial Profile

Phase II study of combination therapy with 5-AZAcytidine, valproic acid, and all-trans retinoic acid [tretinoin] in patients with myelodysplastic syndromes and other myeloid malignancies who cannot receive intensive chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2011

At a glance

  • Drugs Azacitidine (Primary) ; Valproic acid (Primary) ; Tretinoin
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AZAVATRA
  • Most Recent Events

    • 01 May 2010 Actual end date (May 2010) added as reported by ISRCTN: Current Controlled Trials.
    • 01 May 2010 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 16 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top